Quick Comparison

ALCARAniracetam
Half-Life4-5 hours1-2.5 hours
Typical DosageStandard: 500-2000 mg daily in 1-2 doses. For cognitive support: 1000-2000 mg daily. For neuropathy: 1500-3000 mg daily. Take in the morning — may be mildly stimulating.Standard: 750-1500 mg daily in 2 divided doses. Must be taken with fat for absorption (fat-soluble). Some users take up to 3000 mg daily.
AdministrationOral (capsules, powder). Well-absorbed on an empty stomach.Oral (capsules, powder). Must be taken with dietary fat for proper absorption due to lipophilicity.
Research Papers9 papers10 papers
Categories

Mechanism of Action

ALCAR

ALCAR crosses the blood-brain barrier via the organic cation transporter (OCTN2) more effectively than L-carnitine. In neurons, it is hydrolyzed by carnitine acetyltransferase to donate its acetyl group to coenzyme A, forming acetyl-CoA—which can then be used for acetylcholine synthesis via choline acetyltransferase, effectively providing raw material for the memory neurotransmitter. ALCAR also transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system for beta-oxidation and ATP production. ALCAR activates nerve growth factor (NGF) signaling, possibly through modulation of NGF receptor (TrkA) expression or downstream MAPK/ERK pathways. It has antioxidant properties, reducing lipid peroxidation in mitochondrial membranes and scavenging free radicals. These mechanisms support cognitive function and neuroprotection.

Aniracetam

Aniracetam is a positive allosteric modulator of AMPA receptors, binding to the allosteric site and slowing receptor desensitization, which prolongs excitatory postsynaptic currents and facilitates long-term potentiation. It also modulates group II metabotropic glutamate receptors (mGluR2/mGluR3), which regulate presynaptic glutamate release. Uniquely among racetams, aniracetam increases dopamine and serotonin release in the prefrontal cortex via modulation of monoamine transporter activity and vesicular release, contributing to its anxiolytic and mood-enhancing effects. It reduces GABAergic inhibition in the hippocampus through indirect modulation of GABA-A receptors, facilitating NMDA receptor activation and memory consolidation. The lipophilic phenylacetyl group enables rapid blood-brain barrier penetration.

Risks & Safety

ALCAR

Common

Nausea, fishy body odor, restlessness, gastrointestinal discomfort.

Serious

May increase agitation in Alzheimer's patients. TMAO production may be a cardiovascular concern with chronic high doses.

Rare

Seizures in susceptible individuals, increased thyroid activity.

Aniracetam

Common

Headache (mitigated by choline supplementation), mild gastrointestinal discomfort, insomnia.

Serious

No serious adverse effects documented at standard doses.

Rare

Anxiety or overstimulation in sensitive individuals, dizziness.

Full Profiles